Related Experiment Video
Updated: Apr 4, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Treatment of Autosomal Dominant Polycystic Kidney Disease: Integrating Clinical Practice Guidelines, Patient
1Michael Stern Laboratory for Polycystic Kidney Disease, Westmead Institute for Medical Research, The University of Sydney and Department of Renal Medicine, Westmead Hospital, Western Sydney Local Health District, Sydney, Australia.
Abstract:
Autosomal dominant polycystic kidney disease is a systemic, hereditary disorder requiring life-long, multidisciplinary management. Approximately half of affected individuals progress to kidney failure by age 60 years. Recent advances in genetics, imaging, and disease pathophysiology have enabled earlier diagnosis and improved risk stratification and led to the development of disease-modifying therapies (such as tolvaptan) for high-risk patients. Despite the availability of comprehensive clinical practice guidelines, real-world implementation is hindered by disease heterogeneity, psychosocial impacts, and the need for individualized care. The aim of this narrative review is to facilitate guideline implementation by integrating evidence from patient perspectives and real-world effectiveness and offering strategies to overcome practical barriers.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Chronic Pancreatitis II: Collaborative Care
Assessment:
Kidney Transplant I: Introduction

